The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta2-agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients ≥18 years old with asthma. Airsupra is the first combination of a SABA and an ICS to become available in the US. It is not approved for use as maintenance therapy.
STANDARD TREATMENT ― The inhaled SABAs albuterol and levalbuterol are used as needed for rapid relief of asthma...
ISSUE
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo, MenQuadfi)1 and two meningococcal serogroup B vaccines (MenB; Bexsero, Trumenba) are available in the US (see Table 2).
MENINGOCOCCAL DISEASE — Six serogroups of N. meningitidis (A, B, C, W, X, and Y) cause most cases of invasive meningococcal disease (IMD) worldwide. Most US cases are caused by serogroups B, C, and Y. Infection rates …